Viewing Study NCT00153582



Ignite Creation Date: 2024-05-05 @ 11:50 AM
Last Modification Date: 2024-10-26 @ 9:15 AM
Study NCT ID: NCT00153582
Status: UNKNOWN
Last Update Posted: 2006-02-22
First Post: 2005-09-08

Brief Title: WT1 Peptide Vaccination in Acute Myeloid Leukemia AML
Sponsor: Charite University Berlin Germany
Organization: Charite University Berlin Germany

Study Overview

Official Title: Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in AML
Status: UNKNOWN
Status Verified Date: 2005-09
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: In this trial HLA-A2 patients with active AML are vaccinated with a peptide from the leukemia-associated antigen WT1 together with immunological adjuvants keyhole limpet hemocyanin KLH as T-helper protein and granulocyte macrophage colony stimulating factor GM-CSF 4 times bi-weekly then monthly
Detailed Description: In this phase II trial HLA-A2 patients with active AML without curative treatment option are vaccinated with WT1 126-134 peptide mixed with adjuvant KLH as T-helper protein and GM-CSF 4 times bi-weekly then monthly

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
Carreras 0425f None None None